Kestra Medical raises FY26 revenue guidance to $93 million; Q3 revenue up 63%
Kestra Medical Technologies reported revenue of $24.6 million for the quarter ended January 31, 2026, up 63% from the prior year, and raised its fiscal 2026 revenue guidance to $93 million from $91 million. The net loss widened to $34.2 million from $21.8 million, so shareholders are weighing faster sales growth against larger losses.
Key points
- Q3 FY26 revenue was $24.6 million, up 63% from $15.1 million in the prior year period.
- Gross margin was 52.6% versus 43.4% a year earlier; gross profit was $12.9 million versus $6.5 million.
- GAAP net loss was $34.2 million versus $21.8 million; adjusted EBITDA loss was $21.2 million versus $16.3 million.
- FY26 revenue guidance rose to $93 million from $91 million (initial guidance $85 million); cash and cash equivalents were $291 million at January 31, 2026.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.